Peptide Therapeutics intermediate
ALRN-6924 - First-in-Human (NCT02264613)
First-in-human trial of ALRN-6924, a dual MDM2/MDMX inhibitor peptide. This peptide or oligopeptide is studied for its biological activity, structure-activit...
By Encyclopeptide Editorial | 1 min read
alrn-6924-first-in-human-nct02264613 peptide research
Overview
First-in-human trial of ALRN-6924, a dual MDM2/MDMX inhibitor peptide.
Clinical Significance
This topic has important implications for peptide research and clinical applications.
References
- Encyclopeptide Database. “ALRN-6924 - First-in-Human (NCT02264613)” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about ALRN-6924 - First-in-Human (NCT02264613) with interactive quizzes on Wikipept.
Take a Quiz on Wikipept